StockData

BGM vs Jaguar Health

BGM and JAGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BGM and JAGX compare

Jaguar Health grew revenue faster over the last twelve months (136% versus 51.1% for BGM).

BGM scores higher on the StockData Score (9 against 3 for Jaguar Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBGMJAGX
Size and price
Market cap–$2.2M
Share price$8.01$0.420
Change, 1 year−97.1%−100.0%
Change, 5 years−98.3%−100%
Beta (5Y)1.94–
Employees20647
StockData Score
Total score9 (better)3
Valuation score01 (better)
Growth score22
Performance score2 (better)0
Health score5 (better)0
Dividend score00
Valuation
P/S–0.1×
Growth
Revenue growth (TTM)51.1%136% (better)
Revenue growth, 5Y average−5.4%4.2% (better)
Profitability
Gross margin16.6%82.3% (better)
Operating margin−33.2% (better)−93.1%
Net margin−52.6%–
FCF margin−10.4%–
Return on equity−9.2%–
Return on invested capital−4.8%–
Financial health
Debt / equity0.00–
Interest coverage–−25.9×
Current ratio1.24 (better)0.69
Altman Z-score–−18.45
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%–
Held by insiders52.5%17.1%
Short interest, % of float0.00%4.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.